|
For those that are just joining us, welcome. If this is your 1st email from TopNasdaqStocks.com the timing could not be any better.
Medovex Corp. (MDVX) is on FIRE lately. After coming off of one of our biggest alerts of the year, which ran nearly 1,000% MDVX has done a great job of starting to follow in its footsteps! Why? Since we alerted MDVX a few weeks back at $1.48 the stock has not only seen record volume but day in and day out, the higher highs it continues to hit has put this on A LOT of scanners this month!
That's correct, MDVX has officially hit levels that the stock hasn't seen since October of 2015 and what we think could be the best part of this...the run could be far from finished! Friday (6/10) MDVX climbed to $2.10 during mid day trading and after pulling back from those highs later in the day, an afternoon surge of buying ended up shooting MDVX back up into the mid $1.90 range! If you're still sitting on the sidelines we feel that there could be some BIG POTENTIAL heading into this week.
In just a few short weeks MDVX has managed to run up 42%...and the news flow has become a major catalyst to this latest run. If you thought our last featured company "topped out" when it was up even 50%, you would have left OVER 700% on the table! We're only a few weeks into the month and we strongly feel that MDVX could just be getting its feet off the ground!
If you haven't read the latest new yet, you can do so below and see what the excitement is all about. We will continue to update everyone on new developments as we find them:
Medovex Corporation Announces DenerveX System Pre-Production Milestone With Extensive Live Tissue Model
ATLANTA, GA--(Marketwired - Jun 6, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that its DenerveX™ System has successfully been used in its most extensive live tissue test to date. The company announced that it completed an extensive twelve subject live tissue laboratory using the most stringent standards for Good Laboratory Practice standards (GLP) using the final pre-production model device and generator.
The Company's patented DenerveX System, currently in the final development stages and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.
Read the full release HERE.
Start getting ready for the opening bell as this could once again be an exciting day after the surge in positive market action we've begun to see already this month!
Text Messages Are Received Much Quicker Than Email So If You Have A Cell Phone, Take It Out And Text The Word “NASDAQ” to 77948
|
